Centessa Pharmaceuticals PLC (CNTA)

NASDAQ: CNTA · IEX Real-Time Price · USD
4.34
0.00 (0.00%)
Sep 23, 2022 4:00 PM EDT - Market closed
0.00%
Market Cap 409.43M
Revenue (ttm) n/a
Net Income (ttm) -220.09M
Shares Out 94.34M
EPS (ttm) -2.30
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 97,673
Open 4.28
Previous Close 4.34
Day's Range 4.00 - 4.43
52-Week Range 2.89 - 19.50
Beta n/a
Analysts Sell
Price Target 6.12 (+41.0%)
Earnings Date Aug 15, 2022

About CNTA

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; and SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B. The company also has emerging pipeline products under clinical proof of c... [Read more...]

Industry Biotechnology
IPO Date May 28, 2021
Employees 68
Stock Exchange NASDAQ
Ticker Symbol CNTA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for CNTA stock is "Sell." The 12-month stock price forecast is 6.12, which is an increase of 41.01% from the latest price.

Price Target
$6.12
(41.01% upside)
Analyst Consensus: Sell
Stock Forecasts

News

Centessa Pharmaceuticals Announces Poster Presentation Featuring Novel Orexin Receptor 2 (OX2R) Agonist Discovery Pip...

– Data demonstrate potent efficacy of small-molecule OX2R agonists in a non-clinical model of narcolepsy type 1 (NT1) – – Company recognizes World Narcolepsy Day on September 22 nd   –

4 days ago - GlobeNewsWire

Centessa Pharmaceuticals Announces Non-Human Primate Pharmacokinetic and Safety Data for LB101 (PD-L1xCD47) Demonstra...

Data support continued advancement of LB101 toward IND submission late this year Data support continued advancement of LB101 toward IND submission late this year

1 week ago - GlobeNewsWire

ROSEN, A LEADING LAW FIRM, Encourages Centessa Pharmaceuticals plc Investors to Inquire About Securities Class Action...

New York, New York--(Newsfile Corp. - September 5, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, continues its investigation of potential securities claims on behalf of shareholders of...

2 weeks ago - Newsfile Corp

GLOBALLY RECOGNIZED ROSEN LAW FIRM Encourages Centessa Pharmaceuticals plc Investors to Inquire About Class Action In...

New York, New York--(Newsfile Corp. - August 26, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Ce...

4 weeks ago - Newsfile Corp

CNTA INVESTOR NOTICE: ROSEN, A TOP RANKED LAW FIRM, Encourages Centessa Pharmaceuticals plc Investors with Losses to ...

NEW YORK , Aug 25, 2022 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Centessa Pharmaceut...

4 weeks ago - PRNewsWire

INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Centessa Pharmaceuticals plc with Losses of $100,...

Los Angeles, California--(Newsfile Corp. - August 17, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cent...

1 month ago - Newsfile Corp

ONGOING INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in Centessa Pharmaceuticals plc with Losses of...

Los Angeles, California--(Newsfile Corp. - August 16, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cent...

1 month ago - Newsfile Corp

ONGOING INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Centessa Pharmaceuticals plc with Losses of ...

Los Angeles, California--(Newsfile Corp. - August 15, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cent...

1 month ago - Newsfile Corp

INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in Centessa Pharmaceuticals plc with Losses of $100,00...

LOS ANGELES--(BUSINESS WIRE)---- $CNTA #CNTA--The Schall Law Firm Encourages Investors in Centessa Pharmaceuticals plc with Losses of $100,000 to Contact the Firm

1 month ago - Business Wire

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Centessa Pharmaceuticals plc

New York, New York--(Newsfile Corp. - August 12, 2022) - Pomerantz LLP is investigating claims on behalf of investors of Centessa Pharmaceutical plc (""CNTA" or the "Company") (NASDAQ: CNTA). Such inves...

1 month ago - Newsfile Corp

INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Centessa Pharmaceuticals plc with Losses of $100,000...

LOS ANGELES--(BUSINESS WIRE)---- $CNTA #CNTA--The Schall Law Firm Encourages Investors in Centessa Pharmaceuticals plc with Losses of $100,000 to Contact the Firm

1 month ago - Business Wire

EQUITY ALERT: Rosen Law Firm Encourages Centessa Pharmaceuticals plc Investors with Losses in Excess of $100K to Inqu...

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Centessa Pharmaceuticals plc (NA...

1 month ago - Business Wire

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2022; Provides P...

- Registrational studies of SerpinPC for treatment of Hemophilia B planned for 2H of 2022 –

1 month ago - GlobeNewsWire

Centessa Pharmaceuticals Announces Addition of Harris L. Rotman, PhD, as Senior Vice President of Regulatory Affairs

BOSTON and LONDON, July 25, 2022 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company with a Research & Development (R&D) innovation engine that aims ...

1 month ago - GlobeNewsWire

Centessa Pharmaceuticals Announces Appointment of Dr. Mathias Hukkelhoven to its Board of Directors

BOSTON and LONDON, July 01, 2022 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company with a Research & Development (“R&D”) innovation engine that aim...

2 months ago - GlobeNewsWire

Wall Street Analysts Predict a 128% Upside in Centessa Pharmaceuticals PLC Sponsored ADR (CNTA): Here's What You Shou...

The mean of analysts' price targets for Centessa Pharmaceuticals PLC Sponsored ADR (CNTA) points to a 127.7% upside in the stock. While this highly sought-after metric has not proven reasonably effectiv...

3 months ago - Zacks Investment Research

BMO Capital Sees Almost 300% Upside On Centessa Stock

BMO Capital has initiated coverage on Centessa Pharmaceuticals plc (NASDAQ: CNTA) with a price target of $19 (293% upside), and an Outperform rating. The analyst writes that ZF874 is a differentiated or...

3 months ago - Benzinga

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Centessa Pharmaceuticals plc - CNTA

New York, New York--(Newsfile Corp. - June 15, 2022) - Pomerantz LLP is investigating claims on behalf of investors of Centessa Pharmaceuticals plc ("Centessa" or the "Company") (NASDAQ: CNTA). Such inv...

3 months ago - Newsfile Corp

Centessa Pharmaceuticals Announces Poster Presentation of First Preclinical Data for LockBody® Program at 2022 ASCO A...

Preclinical data showed that single-agent LB101, PD-L1xCD47 LockBody, delivered systemically led to meaningful tumor regressions and was well tolerated Preclinical data showed that single-agent LB101, P...

3 months ago - GlobeNewsWire

Centessa Pharmaceuticals Makes Strategic Decision to Discontinue Clinical Development of Lixivaptan for Autosomal Dom...

- Decision based on reassessment of commercial potential of lixivaptan following recent observation of ALT/AST elevations in ALERT Study -

3 months ago - GlobeNewsWire

Centessa Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Updates

– Company advances innovative rare disease and immuno-oncology portfolio toward ‘4x24' goal of four registrational programs in 2024 –

4 months ago - GlobeNewsWire

Scorpion Therapeutics Appoints Saurabh Saha, M.D., Ph.D. to its Board of Directors

BOSTON--(BUSINESS WIRE)--Scorpion Therapeutics, Inc. (“Scorpion Therapeutics”), a pioneering oncology company redefining the frontier of precision medicine through its Precision Oncology 2.0 strategy, t...

5 months ago - Business Wire

Centessa Pharmaceuticals Reports Fourth Quarter and 2021 Financial Results and Provides Business Update

– Company strengthens strategic focus on rare disease and immuno-oncology assets and details expected upcoming clinical milestones –

5 months ago - GlobeNewsWire

Centessa Pharmaceuticals to Present at the Guggenheim Genomic Medicines & Rare Disease Day

BOSTON and LONDON, March 23, 2022 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA) announced today that Saurabh Saha, MD, PhD, Chief Executive Officer, will present at the Guggenheim Geno...

6 months ago - GlobeNewsWire

Centessa Pharmaceuticals Expands Management Team and Adds to Extensive Development Expertise

BOSTON and LONDON, March 07, 2022 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA) (the “Company”), a clinical-stage company leveraging its innovative asset-centric business model to disc...

6 months ago - GlobeNewsWire